Abvance is developing ABV100, a proprietary, clinically validated combination of insulin and glucagon with a goal of improving glycemic control while reducing hypoglycemia for people with diabetes who require rapid acting insulin
ABV100 has the potential to extend the therapeutic window of insulin by adding the clinical benefits of glucagon in a single formulation
Abvance will host a key opinion leader virtual event on the promise of its transformative insulin-glucagon combination and its product pipeline on September 26, 2024
NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Abvance Therapeutics ("Abvance" or "The Company"), a development stage biopharmaceutical company founded on breakthrough discoveries from the Vanderbilt University Cherrington Lab, today announced that it has secured a $3.9 million Program Related Investment in the form of a loan from The Leona M. and Harry B. Helmsley Charitable Trust. The funding is non-dilutive and will support the pre-clinical development of ABV100, the Company's initial proprietary insulin-glucagon combination candidate.
The risk of hypoglycemia, or low blood glucose, is an ever-present challenge for the insulin-treated across all geographies, including the nearly 10 million people across the USA and the EU/UK alone. Despite advances in diabetes technology, hypoglycemia occurs frequently and can be serious, resulting in seizure, coma, and death. The cost of direct medical treatment for severe hypoglycemia remains significant, as do the indirect costs of lost productivity for affected individuals. Fear of hypoglycemia commonly results in patients underdosing insulin, causing their blood glucose to run dangerously high. This is reflected in large patient data sets that consistently report only 1 in 4 patients who require insulin are currently at glycemic target levels set by the American Diabetes Association and American Association of Clinical Endocrinology. Glucagon, in contrast to insulin, is used to treat hypoglycemia and raises blood sugar ...
